3 terminated, 1 withdrawn. 4 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Terminated 3, Withdrawn 1 |
| Phase 1 | 2 | Terminated 1, Withdrawn 1 |
Follow Flex Pharma, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate Safety & Efficacy of FLX-787-ODT to Treat Fasciculations in Tongue and Appendicular Muscle in Adult Subjects With ALS FLX-787-ODT - Amyotrophic Lateral Sclerosis, Fasciculation | Phase 1 / Phase 2 | Terminated | Flex Pharma, Inc. | 3 | 2018-04-05 | 2018-08-29 |
| Study to Evaluate the Safety & Efficacy of FLX-787-ODT to Treat Fasciculations in Tongue and Upper or Lower Extremity Muscles Most Affected in Subjects With ALS FLX-787-ODT (orally disintigrating tablet) - Amyotrophic Lateral Sclerosis, Fasciculation | Phase 1 / Phase 2 | Withdrawn | Flex Pharma, Inc. | 2017-11-01 | 2018-01-23 | |
| A Study to Assess the Safety and Effectiveness of FLX-787 in Subjects With Charcot-Marie-Tooth Disease Experiencing Muscle Cramps. FLX-787-ODT (orally disintegrating tablet), Placebo ODT - Charcot-Marie-Tooth Disease | Phase 2 | Terminated | Flex Pharma, Inc. | 27 | 2017-10-16 | 2018-08-29 |
| A Study to Assess FLX-787 in Subjects With Motor Neuron Disease Experiencing Muscle Cramps. FLX-787-ODT (orally disintegrating tablet), Placebo ODT - Motor Neuron Disease | Phase 2 | Terminated | Flex Pharma, Inc. | 54 | 2017-07-28 | 2018-08-29 |
Amyotrophic Lateral Sclerosis (3) · Fasciculation (2) · Muscle Cramp (2) · Nervous System Diseases (2) · Neurodegenerative Diseases (2) · Neuromuscular Diseases (2) · Spasm (2) · Charcot-Marie-Tooth Disease (1) · Hereditary Sensory and Motor Neuropathy (1) · Motor Neuron Disease (1) · Muscular Atrophy, Spinal (1) · Nervous System Malformations (1)
United States (4)
Bjorn Oskarsson, MD (1) · Nicolas Johnson, MD (1)